1. Introduction {#sec1}
===============

The health status of the Czech population can be seen as very vulnerable, mainly because of the high risk of cancer especially in younger age. This fact is confirmed by data in Globocan 2008 \[[@B1]\]. Cancer diagnoses are registered since 1959. The IARC criteria are used were for their notificationed since May 1976 by criteria of the IARC. The annual surveys of Health Information and Statistics of the Czech Republic \[[@B2]\] confirmed the continued trend of cancer occurrence, observed in the Czech areas from 1905 \[[@B3]\] and continuously described from 1933 \[[@B4]\]. The cancer incidence increased from 24,471 (254.4/100,000) in 1959 over 35,407 (347.5/100,000) in 1977 to 78,846 (751.5/100,000) in 2009 \[[@B2]\]. In view of new diagnostic and treatment modalities, the prevalence of cancers (ICD-10: C00-97, D00-09) increased from 174,311 (1,682.2/100,000) in 1989 to 461,545 (4,510/100,000) in 2005. Under the conditions of continuous diagnostics, treatment, medical surveillance, and cancer evidence, the survivors can reach in 2015 nearly 317,000 cases in men (of which 33.2% in age 35--64 years) and 434,000 in women (of which 42.6% in age 35--64 years) \[[@B5]\]. The differences between the numbers of cases and numbers of persons indicated the multiple malignant neoplasms (MMNs). After the preliminary report of their trend \[[@B6]\], this paper is another contribution to this issue.

2. Methods {#sec2}
==========

The data of MMNs were based on the number of cancers reported to the Czech Cancer Registry between May 1976 and December 2005 and were verified and anonymised up to October 17, 2007. The percentage of multiple cancers of all diagnoses (ICD-10: C00-97, D00-09, D37-48, i.e. including the skin cancer) in males and females was compared with the number of newly diagnosed cases in the same codes. The primary and subsequent cancers were prepared in contingency tables and analysed by age, time and space distribution, and clinical stages of early (ST I, II), advanced (ST III, IV), and unknown cases. Their input data correspond with the classification of diseases at the time of diagnosis and with the level of cancer evidence in 14 Czech regions.

3. Results {#sec3}
==========

A total of 1,486,984 new malignant neoplasms (50.9% men, 49.1% women) were registered in the Czech Cancer Registry between 1976 and 2005. This number includes 1,430,458 (96.2%) cancers (C00-97), 42,630 (2.9%) neoplasms in situ (D00-09), and 13,896 (0.9%) neoplasms of uncertain behaviour (D37-48). Of all newly registered cancers, there were notified 290,312 (19.5%) MMNs. In men were diagnosed 65,292 primary and 89,796 subsequent cancers and in women 59,970 primary and 75,254 subsequent cancers. A total of 84% duplicities were higher in women than 79.6% in men, while triplicities and others (3--6 MMNs) were in 19.1% cases of men and 15.4% of women. In men, there were the most frequent primary cancers of skin 46%, gastrointestinal 13.5% and urinary tract 9.6%, male genital organs 8.1% and respiratory tract 7.7%; in women, there were cancers of skin 39.4%, breast 17.3%, female genital organs 14.7%, and gastrointestinal tract 9.8%. The most frequent MMNs were 53,616 primary and 70,119 subsequent cancers of skin as a warning sign for the risk of following neoplasms. The most frequent subsequent diagnoses following primary cases were 26,790 cancers of gastrointestinal tract (54.6% men, 45.4%), 12,801 of respiratory tract (76.9% men, 23.1% women), 10,704 of urinary tract (66.6% men, 33.4% women), 9,394 of breast (0.9% men, 99.1% women), 5,284 of lymphoid and haematopoietic tissue (54.3% men, 45.7% women), and 6,804 of male and 9,309 of female genital organs ([Table 1](#tab1){ref-type="table"}).

The yearly number of MMNs increased from 2,543 cases in 1976 to 17,091 in 2005, of which the primary cancers increased from 2,365 in 1976 to 5,411 in 1995 and then decreased to 1,983 in 2005, while the subsequent cancers increased from 178 in 1976 to 15,108 in 2005 ([Figure 1](#fig1){ref-type="fig"}). The predominance of unknown stages in both sexes over other stages lasted until 1994; from the next years their number decreased especially in the early stages of primary cancers. The percentage occurrence of stage IV was permanently higher in men than in women.

Let us see the situation in age groups. The values of the primary cancers in age group up to 49 years are 8.3% cases in men and 15.7% in women, in group 50--69 years 52.4% in men and 47.8% in women, in group 70--79 years 31.3% in men and 26.7% in women, and in group over 80 years 8% in men and 9.8% in women. After the exclusion of unknown stages, the numbers of early stages were higher in men in group of 70--79 years, in women in group up to 49 years, and in group over 80 years. The numbers of advanced stages were higher in men in group of 50--79 years.

Of the total 65,292 primary cancers in men, were diagnosed 24,263 (37.1%) cases of early stages (of which 28.2% ST I) and 6,051 (9.3%) cases of advanced stages (of which 4.2% ST IV); the unknown stages featured 34,978 (53.6%) cases. Of the total 59,970 primary cancers in women were diagnosed 27,922 (46.6%) cases of early stages (of which 32.6% ST I), 5,707 (9.5%) cases of advanced stages (of which 3.2% ST IV); the unknown stages featured 26,341 (43.9%) cases. The specific position presents 22,607 subsequent cancers of advanced stages (ST III, IV), of which 6,172 cases (i.e. 12.4% of 49,717) followed primary ST I, 2,865 cases (i.e. 17.3% of 16,533) followed primary ST II, 1,905 cases (i.e. 24.1% of 7,890) followed primary ST III, 1,355 cases (i.e. 27.2% of 4,976) followed primary ST IV, and 10,310 cases (i.e. 12% of 85,934) followed primary unknown stages ([Table 2](#tab2){ref-type="table"}). The number of subsequent advanced stages increased with the advanced stage of primary disease.

The geographical distribution of MMNs by stages during 1976--2005 shows relevant maps (Figures [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, [8](#fig8){ref-type="fig"}, [9](#fig9){ref-type="fig"}, [10](#fig10){ref-type="fig"}, and [11](#fig11){ref-type="fig"}). The most frequent values of primary-subsequent cancers of 14 regions reached the population of Northern Moravia---primary 12.7% and subsequent 13.7%, Prague---primary 11.8% and subsequent 11.8%, and Southern Moravia---primary 11.8% and subsequent 11.7%. The distribution of advanced stages presents two percentage values.

The comparison with total advanced stages in subsequent cancers was higher in regions nos. 11 (12.7%), 14 (12.1%), 4 (9.7%), and 1 (9.5%), while the comparison with all subsequent cancers in the relevant region was higher in regions nos. 6 (15.4%), 7 (14.7%), 4 (13.6%), 5 (13.6%) and 13 (12.4%) as an indicator of late diagnosis of subsequent cancer during medical surveillance ([Table 3](#tab3){ref-type="table"}). Of the various comparisons are presented 9,037 advanced stages of subsequent cancers following primary neoplasms with higher value of 1603 (35.7%) gastrointestinal tract in men and 1718 (37.8%) in women, 1489 (33.2%) respiratory tract in men and 636 (14%) in women, 843 (18.5%) breast, 742 (16.3%), female genital organs, 498 (11.1%) male female genital organs, and 376 (8.4%) urinary tract in men and 218 (4.8%) in women ([Figure 2](#fig2){ref-type="fig"}).

Up to October 17, 2007, there were registered of 65,292 primary cancers of men 18,887 (28.9%) surviving and 46,405 (71.1%) deaths, of 59,970 primary cancers of women 22,274 (37.1%) surviving and 37,696 (62.9%) deaths. Of total surviving cases were 54.7% early stages in men and 58% in women, 5% advanced stages in men and 5.2% in women; the unknown stages featured 40.3% in men and 36.9% in women. Of total deceased cases were 30% early stages in men and 39.8% in women, 11% advanced stages in men and 12.1% in women; the unknown stages featured 11% in men and 12.1% in women.

4. Discussion {#sec4}
=============

From ongoing analysis of Cancer Registry database were published the results of the MMNs of breast \[[@B7]\], skin \[[@B8]\], prostate \[[@B9]\], gastrointestinal tract \[[@B10]\], brain \[[@B11]\], lung \[[@B12]\], head and neck \[[@B13]\], testis \[[@B14]\], and penis cancer \[[@B15]\]. We pointed to the current and future relationships of MMNs with ethical and economic burden of the Czech population \[[@B16]\]. We used experiences of more than 50 references, concerning the MMNs. Unfortunately the excellent source which analysed the MMNs of SEER database \[[@B17]\] did not contain data about clinical stages as well as the most of another recent reference \[[@B18]\].

Registered new cases of malignant neoplasms contain also other primary subsequent cancer diagnoses, first described by Billroth and von Winiwarer in 1889 \[[@B19]\]. As their possible causes were assessed the previous radiotherapy \[[@B20]--[@B23]\] and chemotherapy \[[@B24]--[@B28]\], dialysis \[[@B29]\], transplantation \[[@B30]--[@B32]\], and genetic predisposition \[[@B33], [@B34]\]. Their relationship for the risk of the MMNs was not statistically significant. Nevertheless, there is an agreement that the mutual coincidence of these causes can promote the occurrence of subsequent cancers with high burden on patients, their families, and oncologists, including the extraordinary difficulty of palliative care in the terminal period.

It can be assumed that the dispensary care can bring except the metastasis also other topographically and histologically different cancers. Their treatment has similar conditions by clinical stages even when the subsequent cancer can change the treatment scheme of the primary disease. 22,607 advanced stages, that is, 13.7% of all 165,050 subsequent cases during 29 years---is it high or low number? It is important to note that the number of subsequent advanced stages increased with advanced stage of primary disease. These results can contribute to the algorithms of dispensary care and early detection of the subsequent neoplasms. During 1977--2005, nearly every fifth cancer disease of the Czech population was associated with the occurrence of histologically different neoplasms.

The presented maps of MMNs by clinical stages are an example of using spatial analysis in our epidemiological research. Spatial epidemiology is the study of the geographical variation in disease risk, incidence, or prevalence \[[@B35]\]. As a growing field of research, spatial epidemiology provides new insights into multiple cancers as it pertains also to the management of permanent medical surveillance in cancer patients \[[@B36]\] and prevention in the health population by modern visualization \[[@B37]\].

5. Conclusion {#sec5}
=============

Over 29 years, nearly one in five cancers registered in the Czech population was associated with additional cancer. A total of 165,050 subsequent neoplasms 13.7% were diagnosed in the advanced stage. The results suggest that information about multiple neoplasms and their clinical stages is necessary as a part of annual statistical cancer report. The most of subsequent advanced stages can be prevented by the therapeutic guidelines.
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###### 

New cancers and multiple malignant cases based on the Czech Cancer Registry 1976--2005 (up to October 17, 2007, data in 1976 from May).

  Malignant neoplasm           ICD-10    Men      Women                                          
  ---------------------------- --------- -------- ------- ------- ------ -------- ------ ------- ------
  Oral cavity, pharynx         C00-14    20673    2,8     2070    3,2    6241     0,9    540     0,9
  Gastrointestinal tract       C15-26    193547   25,6    8862    13,6   162077   22,2   5882    9,8
  Respiratory tract            C30-39    162315   21,4    5093    7,7    32263    4,4    887     1,5
  Bone, articular cartilage    C40-41    1765     0,2     70      0,1    1320     0,2    50      0,1
  Melanoma of skin             C43       14331    1,9     1626    2,5    15327    2,1    1518    2,5
  Skin                         C44       134727   17,8    30012   46     129787   17,8   23604   39,4
  Mesothelial, soft tissue     C45-49    5489     0,7     321     0,5    5177     0,7    267     0,4
  Breast                       C50       978      0,1     128     0,2    118546   16,2   10352   17,3
  Female genital organs        C51-58    0        0       0       0      115912   15,9   8785    14,7
  Male genital organs          C60-63    74560    9,8     5265    8,1    0        0      0       0
  Urinary tract                C64-68    67530    8,9     6278    9,6    32807    4,5    2221    3,7
  Eye, brain, nervous system   C69-72    10734    1,4     305     0,5    9130     1,3    286     0,5
  Thyroid and other glands     C73-75    3248     0,4     222     0,3    9357     1,3    585     1
  Unspecified sites            C76-80    13539    1,8     392     0,6    13951    1,9    323     0,5
  Lymphoid, haematol. tissue   C81-96    40071    5,3     2667    4,1    35056    4,8    1697    2,8
                                                                                                 
  In situ                      D00-09    7438     1       1161    1,8    35192    4,8    2301    3,8
  Uncertain behaviour          D37-48    6449     0,9     820     1,3    7447     1      672     1,1
                                                                                                 
  Total sites                  C00-D48   757394   100     65292   100    729590   100    59970   100

\% (a): relevant diagnosis in percent of all new cancers.

\% (b): relevant diagnosis in percent of all malignant neoplasms.

###### 

Primary and subsequent neoplasms by clinical stages 1976--2005 (Source: Czech Cancer Registry, up to October, 2007). Values of subsequent neoplasms in advanced stages are in bold.

  Primary           Subsequent   Total    Men     Women
  ----------------- ------------ -------- ------- -------
  ST I              ST I         25936    13486   12450
  ST II             5220         2429     2791    
  **ST III**        **2731**     1331     1400    
  **ST IV**         **3441**     1893     1548    
  Unknown           12389        6317     6072    
                                                  
  Total                          49717    25456   24261
                                                  
  ST II             ST I         5927     2534    3393
  ST II             2728         1055     1673    
  **ST III**        **1310**     529      781     
  **ST IV**         **1555**     735      820     
  Unknown           5013         2175     2838    
                                                  
  Total                          16533    7028    9505
                                                  
  ST III            ST I         2163     953     1210
  ST II             980          389      591     
  **ST III**        **951**      417      534     
  **ST IV**         **954**      473      481     
  Unknown           2842         1427     1415    
                                                  
  Total                          7890     3659    4231
                                                  
  ST IV             ST I         1040     644     396
  ST II             441          260      181     
  **ST III**        **341**      191      150     
  **ST IV**         **1014**     559      455     
  Unknown           2140         1334     806     
                                                  
  Total                          4976     2988    1988
                                                  
  Unknown           ST I         26757    15184   11573
  ST II             6653         3661     2992    
  **ST III**        **4324**     2483     1841    
  **ST IV**         **5986**     3807     2179    
  Unknown           42214        25530    16684   
                                                  
  Total                          85934    50665   35269
                                                  
  Total all sites                165050   89796   75254

###### 

Advanced stages of subsequent neoplasms by regions 1976--2005 (Source: Czech Cancer Registry, up to October, 2007). Names of regions were changed to numbers because of anonymization.

  Region   ADV-EAR   ADV-ADV   ADV-UNKN   Total   \% (a)     \% (b)
  -------- --------- --------- ---------- ------- ---------- ----------
  1        922       290       498        1710    **9,5**    8,8
  2        781       295       455        1531    8,5        11,6
  3        679       213       338        1230    6,8        10,6
  4        818       357       564        1739    **9,7**    **13,6**
  5        299       118       196        613     3,4        **13,6**
  6        793       261       434        1488    8,3        **15,4**
  7        375       112       186        673     3,7        **14,7**
  8        284       106       232        622     3,5        8,5
  9        321       99        217        637     3,5        8,7
  10       391       180       309        880     4,9        11,3
  11       1116      425       737        2278    **12,7**   11,8
  12       675       186       409        1270    7,1        8
  13       568       208       337        1113    6,2        **12,4**
  14       1015      410       748        2173    **12,1**   9,6

ADV-EAR: advanced stages of subsequent cancers following early stages of primary cancers.

ADV-ADV: advanced stages of subsequent cancers following advanced stages of primary cancers.

ADV-UNKN: advanced stages of subsequent cancers following unknown stages of primary cancers.

\% (a): percent of total advanced stages in subsequent cancers.

\% (b): percent of subsequent cancers in the relevant region.
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